Co-Diagnostics
CODX
38 hedge funds and large institutions have $1.81M invested in Co-Diagnostics in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
38% more call options, than puts
Call options by funds: $11K | Put options by funds: $8K
3% more funds holding
Funds holding: 37 → 38 (+1)
0.02% less ownership
Funds ownership: 0.6% → 0.58% (-0.02%)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
58% less capital invested
Capital invested by funds: $4.29M → $1.81M (-$2.48M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$110K |
| 2 |
VF
Virtu Financial
New York
|
+$34.6K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$30.5K |
| 4 |
Squarepoint
New York
|
+$23.9K |
| 5 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
+$15.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KOC
Koss-Olinger Consulting
Gainesville,
Florida
|
-$44K |
| 2 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$42.8K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$30.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$29.2K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$16.3K |
CODX Hedge Fund Activity: Q1 2025 in Review
38 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q1 2025, worth a combined $1.81M — down 58% from $4.29M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CODX positions and 5 closed out — a net gain of 2 holders — while 8 added to existing stakes and 10 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $110K. The largest seller was Koss-Olinger Consulting, exiting entirely with an estimated $44K sold.
- 38 institutional investors held Co-Diagnostics (CODX) as of Q1 2025, up from 37 in Q4 2024.
- Funds reported $1.81M of Co-Diagnostics stock for Q1 2025, down 58% quarter-over-quarter.
- 7 funds opened new Co-Diagnostics positions in Q1 2025 and 5 closed out, a net change of +2 holders.
- The largest Co-Diagnostics buyer in Q1 2025 was Citadel Advisors, an estimated $110K added.
- The largest Co-Diagnostics seller in Q1 2025 was Koss-Olinger Consulting, an estimated $44K sold.
Based on aggregated 13F filings for Q1 2025.